Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Omega-3 Ethyl Esters 2 g Clear all

Conditions: Obesity, Fertility
Interventions: LOVAZA, GnRH; Dietary Supplement · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver, Non-Alcoholic Steatohepatitis
Interventions: Vitamin E [(all-rac)-α-tocopheryl acetate], Omega-3 fatty acid (DHA EE), Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate], Placebo; Dietary Supplement · Combination Product · Other
Lead sponsor: Naga P. Chalasani; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 10 more

Conditions: Hypertriglyceridemia
Interventions: rosuvastatin 40 mg tablet, Epanova™ QD (2 x 1 g capsules), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose, Multiple (20) oral doses of 2 g Vascepa® every 12 hours; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 18
States / cities: Sacramento, California • Golden, Colorado • Miami, Florida + 13 more

Conditions: Non-alcoholic Fatty Liver Disease, Fatty Liver
Interventions: Omega-3-acid ethyl esters, Placebo; Drug
Lead sponsor: Boston University; Other
Eligibility: 13 Years to 17 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Postoperative Delirium
Interventions: Omega-3 Ethyl Esters 4 g, Omega-3 Ethyl Esters 2 g; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 65 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Healthy
Interventions: Aspirin, omega-3 acid ethyl esters; Drug
Lead sponsor: Sanford Research; Other
Eligibility: 21 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Metabolic Syndrome, Hypertriglyceridemia
Interventions: omega-3 acid ethyl esters, extended release niacin, placebo, combined treatment; Drug
Lead sponsor: University of South Dakota; Other
Eligibility: 40 Years to 69 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 80
States / cities: Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more

Conditions: Hypertriglyceridemia, Diabetic Neuropathy
Interventions: omega-3-ethyl esters, Placebo; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Hypertriglyceridemia
Interventions: Omega-3-Acid Ethyl Esters; Drug
Lead sponsor: Jewish Hospital, Cincinnati, Ohio; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertriglyceridemia
Interventions: warfarin, omefas, omega-3-acid ethyl esters; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hypertriglyceridemia
Interventions: Omega-3-acid ethyl esters, Placebo; Drug
Lead sponsor: Babu Balagopal; Other
Eligibility: 10 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Wilmington, Delaware • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Primary Hypercholesterolemia
Interventions: P-OM3, Placebo; Drug
Lead sponsor: Provident Clinical Research; Other
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Addison, Illinois

Search by objective public record fields.

Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women

Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)

Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

Study of Fish Oil to Reduce ALT Levels in Adolescents

The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery

Effects of Omacor and Aspirin on Platelet Function

Niacin, N-3 Fatty Acids and Insulin Resistance

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

Lovaza® and Microvascular Function in Type 2 Diabetes

Triglyceride Lowering Study

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

Fish Oil Study for High Triglyceride Levels in Children

Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia